Danaher (NYSE:DHR – Free Report) had its price objective raised by The Goldman Sachs Group from $210.00 to $250.00 in a research note released on Monday. The Goldman Sachs Group currently has a buy rating on the conglomerate’s stock.
A number of other research firms have also recently commented on DHR. Royal Bank Of Canada lifted their price target on shares of Danaher from $200.00 to $215.00 and gave the stock an “outperform” rating in a report on Wednesday, July 22nd. Citigroup initiated coverage on Danaher in a research report on Tuesday, May 26th. They issued a “buy” rating and a $230.00 target price for the company. Piper Sandler assumed coverage on Danaher in a research note on Thursday, June 11th. They issued a “neutral” rating and a $200.00 target price on the stock. Guggenheim dropped their price target on Danaher from $235.00 to $200.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Finally, Wells Fargo & Company decreased their price objective on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $230.23.
View Our Latest Stock Report on DHR
Danaher Trading Down 0.1%
Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the prior year, the business earned $0.77 earnings per share. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. Equities research analysts predict that Danaher will post 8.53 EPS for the current year.
Danaher Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s payout ratio is 28.42%.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. First Command Advisory Services Inc. increased its stake in Danaher by 4.4% during the 4th quarter. First Command Advisory Services Inc. now owns 1,104 shares of the conglomerate’s stock worth $253,000 after purchasing an additional 47 shares in the last quarter. Studio Investment Management LLC lifted its stake in Danaher by 3.3% in the second quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock valued at $302,000 after buying an additional 51 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of Danaher by 71.6% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock valued at $29,000 after buying an additional 53 shares during the period. JDH Wealth Management LLC increased its position in shares of Danaher by 4.5% during the first quarter. JDH Wealth Management LLC now owns 1,264 shares of the conglomerate’s stock worth $240,000 after acquiring an additional 55 shares in the last quarter. Finally, OneAscent Financial Services LLC increased its position in shares of Danaher by 5.5% during the fourth quarter. OneAscent Financial Services LLC now owns 1,069 shares of the conglomerate’s stock worth $245,000 after acquiring an additional 56 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.
About Danaher
Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.
The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.
See Also
- Five stocks we like better than Danaher
- 3 Energy ETFs Built for Oil’s New $100-Plus Reality
- Can Marvell Keep Up in the Custom AI Chip Race?
- DraftKings Falls 7.6%: Is Kalshi’s NFL Lead Really That Big?
- Gaming Your Portfolio: Should You Add Take-Two Ahead of GTA 6’s November Launch?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
